Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas
- PDF / 1,488,870 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 32 Downloads / 159 Views
RESEARCH ARTICLE
Open Access
Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas Dominique M. O. Higgins1,2* , Maisel Caliva3,4, Mark Schroeder5, Brett Carlson5, Pavan S. Upadhyayula2, Brian D. Milligan1,6, Samuel H. Cheshier7, Irving L. Weissman8, Jann N. Sarkaria5, Fredric B. Meyer3 and John R. Henley3
Abstract Background: Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults, with a median survival of approximately 15 months. Semaphorin 3A (Sema3A), known for its axon guidance and antiangiogenic properties, has been implicated in GBM growth. We hypothesized that Sema3A directly inhibits brain tumor stem cell (BTSC) proliferation and drives invasion via Neuropilin 1 (Nrp1) and Plexin A1 (PlxnA1) receptors. Methods: GBM BTSC cell lines were assayed by immunostaining and PCR for levels of Semaphorin 3A (Sema3A) and its receptors Nrp1 and PlxnA1. Quantitative BrdU, cell cycle and propidium iodide labeling assays were performed following exogenous Sema3A treatment. Quantitative functional 2-D and 3-D invasion assays along with shRNA lentiviral knockdown of Nrp1 and PlxnA1 are also shown. In vivo flank studies comparing tumor growth of knockdown versus control BTSCs were performed. Statistics were performed using GraphPad Prism v7. Results: Immunostaining and PCR analysis revealed that BTSCs highly express Sema3A and its receptors Nrp1 and PlxnA1, with expression of Nrp1 in the CD133 positive BTSCs, and absence in differentiated tumor cells. Treatment with exogenous Sema3A in quantitative BrdU, cell cycle, and propidium iodide labeling assays demonstrated that Sema3A significantly inhibited BTSC proliferation without inducing cell death. Quantitative functional 2-D and 3-D invasion assays showed that treatment with Sema3A resulted in increased invasion. Using shRNA lentiviruses, knockdown of either NRP1 or PlxnA1 receptors abrogated Sema3A antiproliferative and pro-invasive effects. Interestingly, loss of the receptors mimicked Sema3A effects, inhibiting BTSC proliferation and driving invasion. Furthermore, in vivo studies comparing tumor growth of knockdown and control infected BTSCs implanted into the flanks of nude mice confirmed the decrease in proliferation with receptor KD. Conclusions: These findings demonstrate the importance of Sema3A signaling in GBM BTSC proliferation and invasion, and its potential as a therapeutic target. Keywords: Semaphorin, Neuropilin, Plexin, Glioma, Brain tumor stem cells
* Correspondence: [email protected] 1 Mayo Clinic: College of Medicine, Rochester, MN 55905, USA 2 Department of Neurosurgery, Columbia University Medical Center, 710 W. 168th Street, New York, NY 10032, USA Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to t
Data Loading...
